Policy & Regulation
Mirecule expands collaboration with Sanofi to advance FSHD therapy
18 March 2026 - Mirecule Inc, a developer of Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, on Wednesday announced an expansion of its strategic collaboration with Fr...
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
18 March 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Wednesday that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designati...
Alebund Pharmaceuticals signs licensing and equity agreements with R1 Therapeutics
18 March 2026 - Alebund Pharmaceuticals, a China-based, renal-focused biopharmaceutical company, announced on Tuesday that it has signed licensing and equity agreements with R1 Therapeutics Inc, a new...
Apertura Gene Therapy agrees manufacturing collaboration with Viralgen
18 March 2026 - Apertura Gene Therapy, a biotechnology company developing next-generation adeno-associated virus (AAV) capsids for delivering genetic medicines, has formed a strategic manufacturing co...
Humacyte submits Israel MAA for Symvess arterial trauma repair
...
Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment
17 March 2026 - US biopharmaceutical company Sentynl Therapeutics Inc, a wholly-owned subsidiary of Zydus Lifesciences Limited, announced on Monday that it has signed an agreement with PRG S&T, a ...